Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up

View ORCID ProfileNicholas Bussiere, Jie Mei, Cindy Levesque-Boissonneault, Mathieu Blais, Sara Carazo, Francois Gros-Louis, View ORCID ProfileRobert Laforce Jr, Gaston De Serres, View ORCID ProfileNicolas Dupre, View ORCID ProfileJohannes Frasnelli
doi: https://doi.org/10.1101/2021.12.20.21268066
Nicholas Bussiere
1Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas Bussiere
Jie Mei
1Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cindy Levesque-Boissonneault
1Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Blais
2Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Carazo
2Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada
5Institut National de Santé Publique du Québec, Québec City, QC, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Gros-Louis
2Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada
3Faculty of Medicine, Department of Surgery, Université Laval, Québec City, QC, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Laforce Jr
2Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada
6Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Laforce Jr
Gaston De Serres
2Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada
4Faculty of Medicine, Department of Social and Preventive Medicine, Université Laval, Québec City, QC, Canada
5Institut National de Santé Publique du Québec, Québec City, QC, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Dupre
2Centre Hospitalier Universitaire de Québec – Université Laval, Québec City, QC, Canada
6Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada
MD, MSc, FRCP FAAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicolas Dupre
Johannes Frasnelli
1Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Johannes Frasnelli
  • For correspondence: johannes.a.frasnelli{at}uqtr.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background and Objectives Olfactory and gustatory dysfunctions (OD, GD) are prevalent symptoms following COVID-19 and persist in 6%-44% of individuals in the first months after the infection. As only few reports have described their prognosis more than 6 months later, the main objective of this study was to assess the prevalence of OD and GD 11 months after COVID-19. We also aimed to determine test-retest reliability of subjective chemosensory ratings for the follow-up of chemosensory sensitivity, as this measure is often used for remote follow-up.

Methods Inclusion criteria included a PCR-confirmed SARS-CoV-2 infection; exclusion criteria were the presence of other respiratory infections and chronic sinusitis. To assess whether OD and GD had changed compared to pre-pandemic levels, we designed an observational study and distributed an online questionnaire assessing quantitative chemosensory function to healthcare workers 5 and 11 months after COVID-19. Specifically, we assessed olfaction, gustation, and trigeminal sensitivity (10-point visual analog scale) and function (4-point Likert scale) separately. We further assessed clinically relevant OD using the Chemosensory Perception Test, a psychophysical test designed to provide a reliable remote olfactory evaluation. Qualitative chemosensory dysfunction was also assessed.

Results We included a total of 366 participants (mean age of 44.8 years old (SD: 11.7)). They completed the last online questionnaire 10.6 months (SD: 0.7) after the onset of COVID-19 symptoms. Of all participants, 307 (83.9%) and 301 (82.2%) individuals retrospectively reported lower olfactory or gustatory sensitivity during the acute phase of COVID-19. Eleven months later, 184 (50.3%) and 163 (44.5%) indicated reduced chemosensory sensitivity, 32.2% reported impairment of olfactory function while 24.9% exhibited clinically relevant OD. Three variables predicted OD at follow-up, namely chest pain and GD during COVID-19 and presence of phantosmia at 5 months. Olfactory sensitivity ratings had a high test-retest reliability (intraclass correlation coefficient: 0.818 (95% CI: 0.760 - 0.860))

Discussion This study suggests that chemosensory dysfunctions persist in a third of COVID-19 patients 11 months after COVID-19. Subjective measures have a high test-retest reliability and thus can be used to monitor post-COVID-19 OD. OD appears to be a common long-term symptom of COVID-19 important to consider when treating patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported financially by Fonds de recherche du Quebec, Sante (chercheur boursier junior 2 #283144 to JF).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of the CHU de Quebec Universite Laval gave ethical approval for this work (MP 20 2021 5228).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 27, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up
Nicholas Bussiere, Jie Mei, Cindy Levesque-Boissonneault, Mathieu Blais, Sara Carazo, Francois Gros-Louis, Robert Laforce Jr, Gaston De Serres, Nicolas Dupre, Johannes Frasnelli
medRxiv 2021.12.20.21268066; doi: https://doi.org/10.1101/2021.12.20.21268066
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up
Nicholas Bussiere, Jie Mei, Cindy Levesque-Boissonneault, Mathieu Blais, Sara Carazo, Francois Gros-Louis, Robert Laforce Jr, Gaston De Serres, Nicolas Dupre, Johannes Frasnelli
medRxiv 2021.12.20.21268066; doi: https://doi.org/10.1101/2021.12.20.21268066

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Otolaryngology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)